[go: up one dir, main page]

DK3161129T3 - Nerveceller, der udtrykker adenovirus e4orf1 og fremgangsmåder til at fremstille og anvende samme - Google Patents

Nerveceller, der udtrykker adenovirus e4orf1 og fremgangsmåder til at fremstille og anvende samme Download PDF

Info

Publication number
DK3161129T3
DK3161129T3 DK15810918T DK15810918T DK3161129T3 DK 3161129 T3 DK3161129 T3 DK 3161129T3 DK 15810918 T DK15810918 T DK 15810918T DK 15810918 T DK15810918 T DK 15810918T DK 3161129 T3 DK3161129 T3 DK 3161129T3
Authority
DK
Denmark
Prior art keywords
nerv
procedures
cells
preparing
same
Prior art date
Application number
DK15810918T
Other languages
English (en)
Inventor
Liang Qiang
Claude Geoffrey Davis
Daniel Joseph Nolan
Original Assignee
Angiocrine Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiocrine Bioscience Inc filed Critical Angiocrine Bioscience Inc
Application granted granted Critical
Publication of DK3161129T3 publication Critical patent/DK3161129T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/081—Coculture with; Conditioned medium produced by cells of the nervous system neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/086—Coculture with; Conditioned medium produced by cells of the nervous system glial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK15810918T 2014-06-27 2015-06-26 Nerveceller, der udtrykker adenovirus e4orf1 og fremgangsmåder til at fremstille og anvende samme DK3161129T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018056P 2014-06-27 2014-06-27
PCT/US2015/038182 WO2015200897A2 (en) 2014-06-27 2015-06-26 Neural cells expressing adenovirus e4orf1, and methods of making and using the same

Publications (1)

Publication Number Publication Date
DK3161129T3 true DK3161129T3 (da) 2019-11-04

Family

ID=54938963

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15810918T DK3161129T3 (da) 2014-06-27 2015-06-26 Nerveceller, der udtrykker adenovirus e4orf1 og fremgangsmåder til at fremstille og anvende samme

Country Status (10)

Country Link
US (1) US10947500B2 (da)
EP (2) EP3584312A1 (da)
JP (1) JP6889107B2 (da)
KR (1) KR102393885B1 (da)
CN (1) CN106574243B (da)
AU (1) AU2015279552B2 (da)
CA (1) CA2953376C (da)
DK (1) DK3161129T3 (da)
RU (1) RU2745300C2 (da)
WO (1) WO2015200897A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108291196B (zh) 2015-07-20 2021-08-27 安吉克莱茵生物科学有限公司 表达ets转录因子的工程化的内皮细胞
WO2017131926A1 (en) 2016-01-26 2017-08-03 Cedars-Sinai Medical Center SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
CN110121555B (zh) * 2016-09-13 2023-10-20 安吉克莱茵生物科学有限公司 包含工程化内皮细胞的血脑屏障
AU2019209439A1 (en) * 2018-01-22 2020-08-13 Angiocrine Bioscience, Inc. Compositions and methods for treatment of spinal cord injury
AU2019236288A1 (en) * 2018-03-16 2020-09-17 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
US20220288159A1 (en) * 2019-08-07 2022-09-15 Texas Tech University System Ad36e4orf1: a therapeutic treatment for alzheimer's disease
RU2724956C1 (ru) * 2019-10-29 2020-06-29 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский химико-технологический университет имени Д.И. Менделеева" Способ сокультивирования клеток для формирования in vitro модели гемато-энцефалического барьера

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723588B1 (fr) * 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
EP0773287A1 (en) * 1995-11-07 1997-05-14 Bayer Ag Immortalised embryonic hyppocampal cells and their use
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
EP1060242A4 (en) 1998-01-23 2003-09-17 Imclone Systems Inc Purified populations of stem cells
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
JP2001238681A (ja) * 2000-03-03 2001-09-04 Japan Science & Technology Corp 共培養による血液脳関門再構築モデル
US6670138B2 (en) 2000-11-01 2003-12-30 Agy Therapeutics, Inc. Method of diagnosing ischemic stroke via UCP-2 detection
US7439063B2 (en) 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors
US7396680B2 (en) 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
EP1814979B1 (en) * 2004-11-17 2015-04-08 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
WO2006113731A2 (en) * 2005-04-20 2006-10-26 University Of Florida Research Foundation, Inc. Bone marrow-derived neurogenic cells and uses thereof
WO2008039173A2 (en) 2005-09-09 2008-04-03 Government Of The United States Of Amercica, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
JP5113332B2 (ja) * 2005-12-19 2013-01-09 正美 丹羽 血液脳関門インヴィトロ・モデル、病態血液脳関門インヴィトロ・モデル、及びこれを用いた薬物スクリーニング方法、病態血液脳関門機能解析方法、病因解析方法
US8465732B2 (en) * 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
WO2008134539A1 (en) 2007-04-26 2008-11-06 The Regents Of The University Of Michigan Fig4 gene mutations in neurodegeneration
US9709553B2 (en) * 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
AU2009256202B2 (en) 2008-06-04 2014-07-03 FUJIFILM Cellular Dynamics, Inc. Methods for the production of IPS cells using non-viral approach
GB0819530D0 (en) * 2008-10-24 2008-12-03 Univ Sheffield Methods and compositions
WO2010117464A1 (en) * 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Targeted integration into stem cells
CN103237553A (zh) * 2010-07-28 2013-08-07 神经干细胞公司 治疗和/或逆转神经退行性疾病和/或病症的方法
EP2635686B1 (en) * 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
JP6189216B2 (ja) 2010-11-09 2017-08-30 コーネル ユニヴァーシティー 器官再生方法
JP2013017434A (ja) * 2011-07-12 2013-01-31 Kanazawa Univ 神経細胞とグリア細胞を共培養する方法
WO2013029025A1 (en) * 2011-08-24 2013-02-28 The Rockefeller University Compositions and methods to modulate cell activity
US20150024491A1 (en) * 2012-03-27 2015-01-22 Okinawa Institute of Science and Technology Graduate University Neuronal culture medium and method for producing in vivo-like and enhanced synaptogenesis neuron model
CA2874764C (en) 2012-05-30 2022-11-01 Cornell University Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
EP2900801A4 (en) 2012-09-29 2016-06-22 Nortis Inc MICROFLUIDIC SYSTEM FOR THE REPRODUCTION OF FUNCTIONAL UNITS OF TISSUE AND ORGANS IN VITRO
WO2014093270A1 (en) * 2012-12-10 2014-06-19 Virginia Commonwealth University Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7)
EP2946007B1 (en) 2013-01-15 2019-04-10 Cornell University Reprogramming of human endothelium into hematopoietic multi-lineage progenitors by defined factors
WO2014153204A1 (en) * 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions

Also Published As

Publication number Publication date
WO2015200897A2 (en) 2015-12-30
RU2017102573A3 (da) 2019-02-22
EP3161129A4 (en) 2018-01-03
US10947500B2 (en) 2021-03-16
CA2953376C (en) 2024-02-06
CN106574243A (zh) 2017-04-19
JP2017522047A (ja) 2017-08-10
KR102393885B1 (ko) 2022-05-02
RU2017102573A (ru) 2018-08-03
CN106574243B (zh) 2021-02-23
EP3584312A1 (en) 2019-12-25
JP6889107B2 (ja) 2021-06-18
RU2745300C2 (ru) 2021-03-23
CA2953376A1 (en) 2015-12-30
KR20170020721A (ko) 2017-02-23
US20170137781A1 (en) 2017-05-18
WO2015200897A3 (en) 2016-02-18
EP3161129B1 (en) 2019-08-07
AU2015279552B2 (en) 2021-01-21
AU2015279552A8 (en) 2017-02-16
AU2015279552A1 (en) 2017-01-19
EP3161129A2 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
HK1232140A1 (zh) 微類器官以及製造和使用它們的方法
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
DK3224603T3 (da) Nordning og fremgangsmåde til materialekarakteristik
GB2544435B (en) Water-swellable lost circulation materials
SG11201607924TA (en) Figure, platform, and figure system
PL2980328T3 (pl) Element bloku rozsączającego, blok rozsączający i jednostka transportowa
GB201713765D0 (en) Modified adenovirus
SG11201608711RA (en) Material itq-55, method for preparation and use
GB2588261B (en) Apparatus, use of the apparatus and arrangement
DK3161129T3 (da) Nerveceller, der udtrykker adenovirus e4orf1 og fremgangsmåder til at fremstille og anvende samme
PL3197493T3 (pl) Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
GB201420979D0 (en) Regia Pairfect
SI3220893T1 (sl) Sestavek na osnovi COQ10
PT3166945T (pt) Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos
GB201405715D0 (en) Methods, apparatus and materials
DK3225616T3 (da) Alpha-asary-laldehydester, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3097081T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carbaldehyder og 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carboxylater
DK3795130T3 (da) Terapiapparat.
DK3297979T3 (da) Forbindelser og fremgangsmåder til at modulere serotoninreceptorer i periferien
TWI560823B (en) Heat radiation structure, method for making the same, and device using the same
GB201515296D0 (en) Hydrogel compositions, methods for preparing the same and uses thereof
GB201420600D0 (en) The saw
GB201702568D0 (en) Two-parts-are-one password
DK3178837T3 (da) Urlc10-afledt peptid og vaccine, der indeholder dette